<DOC>
	<DOCNO>NCT00917293</DOCNO>
	<brief_summary>The primary objective ass safety effectiveness Pyridoxal 5'-Phosphate reduction express symptom tardive dyskinesia patient schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>Safety Efficacy Pyridoxal 5 ' -Phosphate Treatment Tardive Dyskinesia</brief_title>
	<detailed_description>This study assess effect Pyridoxal 5'-Phosphate reduction express symptom moderate severe tardive dyskinesia patient schizophrenia schizoaffective disorder stable dose , regime , either long act ( i.e . depot/IM ) oral antipsychotic medication , compare placebo . Symptoms assess administration score Abnormal Involuntary Movement Scale ( AIMS ) , specifically item 1 7 ( facial oral movement , extremity movement trunk movement ) visit .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Pyridoxal Phosphate</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>1 . Patients must sign informed consent document indicate understand purpose study , objective , expectation participation study agree participate study . 2 . Meet current diagnostic criterion Schizophrenia ( Disorganized [ 295 . 10 ] , Paranoid [ 295.30 ] , Residual [ 295.60 ] ) , Schizoaffective Disorder [ 295.70 ] define DSMIV least 3 month screen . 3 . Have stable dose regime LAI least 3 injection interval oral antipsychotic least 1 month prior randomization expect remain stable dose regime throughout participation study . 4 . Meet current diagnostic criterion Neuroleptic Induced Tardive Dyskinesia [ 333.82 ] define DSMIV . 5 . Scoring ≥3 ( moderate ) item 8 , `` severity abnormal movement overall '' section AIMS . 6 . Score ≥3 ( moderate ) least one item , ≥2 ( mild ) least 2 item , overall total score ≥5 item 1 7 ( facial oral movement , extremity movement trunk movement ) section AIMS . 7 . Female patient must postmenopausal least 2 year surgically sterile . Women childbearing potential must use agree use reliable form contraception entry participation study . Reliable contraception include oral hormonal contraceptive start least 4 week prior randomization , barrier method condom diaphragm use spermicide , intrauterine device ( IUD ) . 8 . Patients must capable administer study medication assistance administration study medication consistently available throughout study . 1 . Involuntarily commit psychiatric hospital correctional facility . 2 . A primary active DSMIV diagnosis comorbid Axis 1 diagnosis schizophrenia schizoaffective disorder . 3 . PANSS Score &gt; 120 screen visit . 4 . Current medical diagnosis could confound interpretation evaluation indication study ( i.e . Parkinson 's Disease , Huntington 's Chorea , Muscular Dystrophy , Tourette 's Syndrome ) . 5 . History liver cirrhosis , chronic active hepatitis ( know positive serum test within 6 month enrollment ) severe liver dysfunction , liver transaminase ≥3 time ULN screening ( obtain within 30 day prior screen visit ) 6 . History malignancy last 5 year . 7 . Pregnant woman childbearing potential use reliable form contraception ( include oral hormonal contraceptive start least 4 week prior randomization , barrier method condom diaphragm use spermicide , intrauterine device ( IUD ) ) . Women postmenopausal least two year undergone surgical sterilization consider childbearing potential . 8 . Any medical , unstable cardiovascular , respiratory , neurological , renal , hepatic , immunological endocrine , psychiatric condition opinion investigator make patient unsuitable candidate study . 9 . History preexist gastrointestinal narrowing inability swallow oral study medication whole aid water . 10 . Male female patient BMI ≥20 . 11 . Significant , ongoing alcohol drug dependency within 3 month screen define DSMIV ( nicotine exclusionary ) . 12 . Significant risk suicide violent behavior clinically assess investigator . 13 . Participation investigational drug device study within 30 day randomization . 14 . Patients previously participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Tardive Dyskinesia</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Pyridoxal 5'-phosphate</keyword>
</DOC>